Company Profiles

driven by the PitchBook Platform

MerLion Pharmaceuticals

MerLion Pharmaceuticals
2002 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
Series C LATEST DEAL TYPE
$7M LATEST DEAL AMOUNT
16 INVESTORS
Description

Developer of anti-bacterial drugs for the treatment of urinary tract infections. The company engages in research and development of anti-bacterial drugs for the treatment of urinary tract infections and the eradication of helicobacter pylori.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
10 Raeburn Park
Number 02-08
Singapore, 088702
Singapore

+65 6778 0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore MerLion Pharmaceuticals’s full profile, request a free trial.

MerLion Pharmaceuticals Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series C) 13-Jul-2010 $7M 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 01-Mar-2007 0000 000.00 Completed Startup
1. Early Stage VC (Series A) 30-Oct-2002 $13.5M $13.5M Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

MerLion Pharmaceuticals Investments & Acquisitions (2)

Company Name Date Type Deal Size Industry Lead Partner
0000000 21-Aug-2006 000000000000000000 Drug Delivery 0000 0000 00.0
Combinature Biopharm 21-Aug-2006 Merger/Acquisition Biotechnology 0000 0000 00.0
To view this company’s complete investment and acquisition history, request access »

MerLion Pharmaceuticals Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
VI Partners Venture Capital Minority 000 0000 000000 0
Aurelia Private Equity Venture Capital Minority 000 0000 000000 0
BC Brandenburg Capital Venture Capital Minority 000 0000 000000 0
Bio*One Capital Corporate Venture Capital Minority 000 0000 000000 0
HeidelbergCapital Asset Management PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »

MerLion Pharmaceuticals Executive Team (3)

Name Title Board
Seat
Contact
Info
David Dally Chief Executive Officer
Andreas Vente Managing Director

1 Former Executive

You’re viewing 2 of 3 executives. Get the full list »

MerLion Pharmaceuticals Board Members (4)

Name Representing Role Since Contact
Info
Clemens Doppler Ph.D HeidelbergCapital Asset Management Board Member 000 0000
Jean-Philippe Tripet Aravis Board Member 000 0000
Simon Nebel Ph.D Aravis Board Member 000 0000
Swee Yeok Chu EDB Investments Board Member 000 0000
Questions or concerns about this profile? Reach out to website-support@pitchbook.com